MICHAEL MOORE DSc (Hons) PhD (Chairman)
Dr Moore has extensive experience in drug discovery and development and is currently a non-executive director of several private and public bioscience companies, including Mission Therapeutics, of which he was Founder Chairman, NASDAQ-listed Trillium Therapeutics Inc. and Mironid Limited. He is currently Chairman of Chronos Therapeutics and was Founder Chairman of PsiOxus Therapeutics. Dr Moore was previously CEO of Piramed, acquired by Roche in 2008, and Research Director and CSO of Xenova Group plc. Prior to joining the UK biotechnology sector, he had an extensive academic research career, principally at the Paterson Institute for Cancer Research and the University of Manchester Medical School, where he was Honorary Reader in immunology and oncology. Dr Moore holds PhD and DSc degrees from the University of Nottingham, fellowship of the Royal College of Pathologists and is a past Chairman of Cancer Research UK’s drug discovery committee.
STEVEN POWELL BSc (Hons) PhD (Executive Director)
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over 25 years operational and investment experience in pharmaceutical and healthcare R&D. Steven has held four CEO roles, two in public companies, and has led or participated in over 50 corporate transactions.
Operationally, Steven has helped finance and overseen clinical trials in a number of cancer indications including leukaemia, pancreatic cancer, liver cancer, mesothelioma and brain tumours. Since 2010 he has split his time between biotechnology corporate roles and supporting medical research charities.
DAVID MOFFAT BSc (Hons) PhD CChem FRSC (Director of Chemistry)
Dr Moffat joined Macrophage Pharma in November 2014. He had previously been Director of Chemistry at Chroma Therapeutics from 2004 to 2012 having played a leading role in the discovery and development of the Esterase Sensitive Motif technology platform. During this period three molecules from his chemistry team were progressed to the clinic including the macrophage targeted histone deacetylase inhibitors CHR-2845 and CHR-5154. His was also Head of Chemistry at Celltech from 2001 to 2004, prior to its acquisition by UCB, having begun his industrial career there in 1989. He holds a BSc and PhD from the University of Glasgow. He has extensive experience in oncology and inflammation preclinical research, having led groups which have identified numerous clinical development candidates in these therapeutic areas. He is the author and inventor on more than 60 patents and publications.
JOANNE BEDWELL-GARNER BSc (Hons) PhD (Development Director)
Dr Bedwell-Garner brings over 25 years’ experience in the pharmaceutical sector, having held numerous senior Research and Development roles at companies including BTG, where she was Vice President of Non-Clinical Development and was responsible for non-clinical evaluation and translation into the clinic. Prior to this she held senior roles at Protherics, Emergent BioSolutions and Microscience. Dr Bedwell-Garner has a successful track record in taking greater than 15 pre-clinical candidates into clinical development; particularly in the areas of oncology, inflammation, cardiovascular and infectious disease. She obtained a PhD in oncology from University of London.
MARTIN PERRY BSc (Hons) PhD (Director of Biology)
Dr Perry is a specialist in all aspects of pre-clinical discovery and an experienced executive with more than 25 years in the Pharmaceutical and Diagnostic business. Prior to joining Macrophage, he was VP NCE Project Biology at UCB Pharma (2004-2010) having previously been Head of Biochemistry at Celltech which he joined in 1984. He has significant experience of NCE project delivery in oncology, inflammation, autoimmune disease and CNS, both from personal leadership of projects and as a Portfolio Management Team executive member with UCB and Celltech.
ELISABETH PARKER MSc, PhD (Director of Business Development)
Elisabeth has 20 years experience of R&D and commercialisation of translational research through licensing and spin-outs.
Prior to joining Macrophage Pharma, Elisabeth worked for Cancer Research Technology Ltd (CRT), the development and commercialisation arm of Cancer Research UK, and served as a non-executive Director of Arquer Ltd and Azeria Therapeutics Ltd. Prior to joining CRT, Elisabeth was Head of Research at KS Biomedix, a UK quoted Biopharmaceutical company. Elisabeth holds a PhD from the Medical Faculty, Lund University, Sweden.